Macrophage subgroups may play pivotal role in COVID-19 lethality

Many researchers are attempting to identify risk factors for severe or critical COVID-19. A recent paper in the journal Medical Hypotheses in September 2020 suggests that macrophage class activation is one of the factors that determine the clinical phenotype of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Macrophage cell isolated on black background, monocyte, close-up view of immune cell, 3D illustration. Image Credit: Kateryna Kon / Shutterstock
Macrophage cell isolated on black background, monocyte, close-up view of immune cell, 3D illustration. Image Credit: Kateryna Kon / Shutterstock

Macrophages and Variable COVID-19 Risk

Lung macrophages reach this organ in three successive waves at various stages of development. Macrophages in children and in adults must be compared in order to understand how the severity of the disease varies with the degree of development of the macrophage population.

Many studies demonstrate that a sustained rise in IL-6 and IL-1 are linked to poor survival odds in adult respiratory distress syndrome (ARDS), which is a classic feature of severe or critical COVID-19. The latter condition is characterized by the systemic hyper-inflammation called the cytokine storm, or macrophage activation syndrome (MAS).

On the other hand, children are not so susceptible to severe forms of COVID-19, as in Italy, where almost 28,000 patients died, but only 3 below 18 years, as of May 13, 2020. These figures gain relevance when compared to the total number of COVID-19 patients, at ~214,000, and that of pediatric patients, at ~4,500.

Older Adults at Higher Risk of Severe COVID-19

Older people seem to be at a higher risk of death due to COVID-19 because of lower immune function with aging, and this may lead to dysregulation and a cytokine storm.

On the other hand, the apparent protection of children against death due to this infection has been ascribed to a variable pattern of angiotensin converting enzyme 2 (ACE2) receptors in this group, with the level of ACE2 expression in the lung tissue being reduced. However, this is still hypothetical. Moreover, says the author, this would promote rather than protect against a cytokine storm, since the SARS-CoV-2 infection acts via this mechanism.

ACE2 Downregulation Indicates a Poor Prognosis

When ACE2 expression is lowered, the ratio of ACE/ACE2 goes up, which is a poor prognostic factor in lung disease and is also a marker of many chronic illnesses that are linked to a poor outcome in COVID-19. In any case, there does not seem to be any association with the age of the patient and the ACE2 level in bronchoalveolar lavage fluid in earlier studies.

Macrophage Populations Vary with Age

A 2016 paper shows the three waves of macrophages populating the lungs. The first two occur during intrauterine development, in mice, and the third in postnatal life. Thus, children may be expected to have more of the first two lineages of macrophage cells.

Each of these can be traced down to different macrophage groups in the mature lung, with varying cell membrane markers. Some research indicates that ACE2 is not found on all macrophages. The three types of macrophages in the lung do not switch between each other but do interact during immune responses.

Different Macrophage Subgroups React Differently to Infection

The effect of this is that at different ages, the three subgroups of macrophages may mediate a different inflammatory and immune response following exposure to the same antigens. This is especially so with respiratory pathogens, which are countered to a large extent by macrophages in the early phase. The author comments that this “may explain the range of clinical scenarios from asymptomatic, to cold-like symptoms or to dramatic pneumonia.”

The coronavirus spike antigen elicits a human monocyte/macrophage response in vitro via the NF-kappaB pathway, though this finding comes from a study of a single macrophage population. In addition, tissue macrophages resident in the lungs, the memory T cells of the lung, might be cross-reactive to the virus and may facilitate rapid viral clearance. Thus, their presence may prevent progressive COVID-19 by reducing the level of lung inflammation, endothelial damage, and the build-up of macrophages to dangerous proportions.

Different macrophages populations may be similarly found in other organ targets, such as the heart, where the intracardiac fibroblasts or macrophages are necessary for myocardial damage to occur.

Mechanisms Yet to be Uncovered

Some studies suggest that the virus modulates NLRP3 inflammasome activation, which leads to the recruitment of macrophages and leads to widespread damage to the alveoli. The interaction of the inflammasome with the ACE2 receptor may vary with the specific population of macrophages. This may be worth investigating to understand how old vs. young patients with COVID-19 react to the infection.

Patients with severe COVID-19 who required Intensive Care Unit (ICU) care also had a higher proportion and the absolute number of peripheral blood mononuclear cells with CD14+ CD16+ markers, indicating the production of the inflammatory cytokine IL-6.

Other proposed mechanisms underlying the distinctive patterns of lethality in young and old patients with COVID-19 include the absence of involvement of the heart, lung alveoli, and kidneys, different levels of expression of ACE2 and TMPRSS2, as well as a variation in the immune response, which inhibits hyper-inflammatory pathways. These may be linked to the different patterns of macrophages in the lung at various periods of human life.

Implications

In view of the speculative importance of these differences, the study concludes, “Macrophages play a pivotal role in determining COVID-19 severity, but the consequences of macrophage activation in different cell populations are still speculations. More experiments are needed.”

Source

Journal reference:
Dr. Liji Thomas

Written by

Dr. Liji Thomas

Dr. Liji Thomas is an OB-GYN, who graduated from the Government Medical College, University of Calicut, Kerala, in 2001. Liji practiced as a full-time consultant in obstetrics/gynecology in a private hospital for a few years following her graduation. She has counseled hundreds of patients facing issues from pregnancy-related problems and infertility, and has been in charge of over 2,000 deliveries, striving always to achieve a normal delivery rather than operative.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, Liji. (2020, October 05). Macrophage subgroups may play pivotal role in COVID-19 lethality. News-Medical. Retrieved on November 07, 2024 from https://www.news-medical.net/news/20201005/Macrophage-subgroups-may-play-pivotal-role-in-COVID-19-lethality.aspx.

  • MLA

    Thomas, Liji. "Macrophage subgroups may play pivotal role in COVID-19 lethality". News-Medical. 07 November 2024. <https://www.news-medical.net/news/20201005/Macrophage-subgroups-may-play-pivotal-role-in-COVID-19-lethality.aspx>.

  • Chicago

    Thomas, Liji. "Macrophage subgroups may play pivotal role in COVID-19 lethality". News-Medical. https://www.news-medical.net/news/20201005/Macrophage-subgroups-may-play-pivotal-role-in-COVID-19-lethality.aspx. (accessed November 07, 2024).

  • Harvard

    Thomas, Liji. 2020. Macrophage subgroups may play pivotal role in COVID-19 lethality. News-Medical, viewed 07 November 2024, https://www.news-medical.net/news/20201005/Macrophage-subgroups-may-play-pivotal-role-in-COVID-19-lethality.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study finds nirmatrelvir-ritonavir reduces severe COVID-19 and long COVID risks in high-risk patients